Stability of Midazolam Intranasal Formulation for the Treatment of Status Epilepticus in Dogs
Author(s): Elder Deborah Lester, Zheng Bo, White Catherine A, Li Dawei
Issue: Jan/Feb 2011 - Volume 15, Number 1
View All Articles in Issue
Page(s): 74-77
Download in electronic PDF format for $65
Abstract: The purpose of this study was to determine the stability of an extemporaneously prepared intranasal formulation of midazolam for the treatment of status epileptus in dogs. An aqueous solution of midazolam (50 mg/mL) was prepared by dissolving 500 mg of midazolam powder in sterile water for injection containing carbopol (0.4%) and benzalkonium chloride (0.01%), pH 2.8 to 3.0. Five identical formulations were prepared and placed in lightresistant glass containers and stored under refrigeration (3°C to 5°C) and at room temperature (22°C to 24°C). Samples were collected from each container at 0, 2, 4, 8, and at 1, 3, 7, 14, 30, 45, 60, and 90 days. Each sample was diluted to an expected concentration of 200 mcg/mL and assayed using high-performance liquid chromatographic analysis with ultraviolet detection. The formulation was shown to be stable for 30 days under refrigeration and at room temperature. The formulation was shown to be unstable under both storage conditions at and beyond 45 days. Stability is defined as the retention of at least 90% of the initial concentration. It is suggested that the extemporaneously prepared midazolam intranasal formulation can safely be stored for 30 days at room temperature or under refrigeration.
Related Keywords:
Deborah Lester Elder, PharmD, RPh, Bo Zheng, PhD, Catherine A. White, PhD, Dawei Li, DPhil of Pharmacy Candidate, midazolam, benzodiazepines, intranasal administration, dogs, canine, status epilepticus, antiepileptic drug, stability, storage
Related Categories:
PEER-REVIEWED, STABILITIES, COMPATIBILITIES, VETERINARY, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Midazolam Intranasal Formulation for the Treatment of Status Epilepticus in Dogs
Elder Deborah Lester, Zheng Bo, White Catherine A, Li Dawei
|
Jan/Feb 2011
Pg. 74-77
|
Treating Canine Hepatic Disease
Davidson Gigi S
|
May/Jun 2003
Pg. 188-191
|
The Treatment of Canine Atopic Disease
Davidson Gigi S
|
May/Jun 2002
Pg. 210-215
|
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 449-450
|
Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time
Sanchez-Rubio Ferrandez J, Lozano M C, Iglesias I, Sanchez-Rubio Ferrandez L, Rodriguez Vargas B, Moreno Diaz R
|
Sep/Oct 2012
Pg. 431-433
|
Finding the Right Balance: A Nationwide Study of Student Pharmacist Exposure to and Perceptions of Nonsterile Compounding
Fredrickson Mary E, Belcher Faith G, Del Vecchio Kamryn N, Galleher Miranda N, Jugo Leila S, Gothard M David, Pallotta Raneem H, Pallotta Victor A Jr
|
May/Jun 2022
Pg. 242-247
|
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials
Mueller Claudia, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
|
May/Jun 2015
Pg. 261-267
|
Canine Public Servants: Caring for Drug Detection Dogs
Davidson Gigi S
|
Sep/Oct 2008
Pg. 384-390
|
Development and Validation of a Stability-indicating High-performance Liquid Chromatographic Method for Quantification of Progesterone in Compounded Glycerinated Gelatin Troches
Burrows Anna C, Yellepeddi Venkata Kashyap, Snyder Spencer, Wakefield Meagan, Jackson David, Huynh Johnny, Nguyen Khoa, Sayre Casey L
|
Jul/Aug 2019
Pg. 340-350
|
Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal, Levesque Dan, Frye John, Rashid Mamoon
|
Jul/Aug 2020
Pg. 322-326
|